ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 106 filers reported holding ASCENDIS PHARMA A/S in Q4 2018. The put-call ratio across all filers is 0.16 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,568 | -99.7% | 29,218 | +123.0% | 0.01% | +150.0% |
| Q2 2022 | $1,218,000 | +413.9% | 13,105 | +548.8% | 0.00% | – |
| Q1 2022 | $237,000 | -39.8% | 2,020 | -42.3% | 0.00% | -100.0% |
| Q1 2020 | $394,000 | -70.2% | 3,500 | -74.5% | 0.00% | -66.7% |
| Q3 2019 | $1,320,000 | -18.3% | 13,700 | -46.9% | 0.00% | -25.0% |
| Q4 2018 | $1,616,000 | +12.2% | 25,799 | +27.0% | 0.00% | +33.3% |
| Q3 2018 | $1,440,000 | -25.2% | 20,315 | -29.8% | 0.00% | -40.0% |
| Q2 2018 | $1,926,000 | – | 28,952 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |